Last updated: February 19, 2026
Who Are the Primary Suppliers of Adagrasib?
Adagrasib (MRTX849) is a KRAS G12C inhibitor developed by Mirati Therapeutics. As a targeted oncology agent, its supply chain involves multiple stakeholders, including raw material producers, contract manufacturing organizations (CMOs), and distribution channels. Currently, Mirati Therapeutics retains control over clinical and commercial production; however, certain suppliers and partners are involved in various stages.
Manufacturing and Supply Chain Breakdown
| Stage |
Main Participants |
Details |
| Raw Material Supply |
Chemical suppliers for key intermediates |
Several suppliers provide raw chemicals, such as advanced intermediates and reagents. Exact names are proprietary but include specialized fine chemical manufacturers. |
| Active Pharmaceutical Ingredient (API) Manufacturing |
Contract manufacturing organizations (CMOs) under Mirati |
CMOs such as WuXi AppTec and Cambrex may produce APIs for clinical supply. Commercial-scale production is likely conducted by Mirati’s internal facilities or strategic partners, with limited public disclosure. |
| Formulation and Packaging |
Contract packagers and formulators |
Typically U.S.-based CMOs with expertise in sterile and oral dosage forms. Specific partners are undisclosed. |
| Distribution and Logistics |
Global pharmaceutical distributors |
Large firms like McKesson, Cardinal Health, and AmerisourceBergen distribute to healthcare providers and specialty pharmacies. |
Major Players in the Market
- Mirati Therapeutics: Developer and primary producer for clinical and commercial supplies.
- WuXi AppTec: Offers CMO services for API synthesis and early-stage manufacturing.
- Cambrex: Supplies chemical intermediates and supports process development.
- Other Chemical Suppliers: Various undisclosed firms provide raw materials; names are rarely publicly disclosed due to confidentiality agreements.
Supply Chain Risks and Considerations
- Dependence on Limited Raw Material Suppliers: Potential bottlenecks if proprietary chemicals face shortages.
- Manufacturing Capacity Constraints: Limited commercial-scale facilities can lead to supply delays.
- Regulatory Compliance: Strict quality standards influence supplier selection and monitoring.
- Geopolitical Factors: International trade restrictions or tariffs can impact raw material sourcing.
Market Trends Affecting Supply
- Growing Demand: Increased use in targeted therapies for KRAS G12C-mutated cancers elevates demand.
- Manufacturing Expansion: Mirati and CMOs invest in capacity to meet clinical and commercial needs.
- Supply Chain Consolidation: Larger chemical and CMO firms expand their capabilities for oncology drugs.
Conclusion
The primary source of adagrasib is Mirati Therapeutics, supported by specialized CMOs like WuXi AppTec and Cambrex in early-stage and manufacturing processes. Raw material inputs originate from an industry network of chemical suppliers, usually undisclosed publicly. The supply chain involves multiple intermediaries, with ongoing capacity expansion to support rising demand.
Key Takeaways
- Mirati Therapeutics controls the core supply of adagrasib, utilizing partnerships with external CMOs for manufacturing.
- WuXi AppTec and Cambrex are significant players in the API production process.
- Raw material sourcing depends on proprietary chemicals supplied by specialized chemical companies.
- Supply chain risks include capacity limitations, supplier dependence, and regulatory compliance issues.
- Market growth in targeted oncology therapies is likely to pressure existing supply frameworks.
FAQs
1. Who manufactures adagrasib at a commercial scale?
Mirati Therapeutics is the primary manufacturer for commercial supplies of adagrasib, supported by external CMOs during development phases.
2. Are there alternative suppliers for adagrasib's raw materials?
Most raw materials are sourced from specialized chemical companies, which are often undisclosed to protect proprietary processes.
3. What risks could disrupt adagrasib supply?
Capacity shortages, raw material shortages, regulatory issues, and geopolitical disruptions pose potential risks.
4. Are there global versions of adagrasib available?
As of now, adagrasib is approved and marketed primarily in the U.S. and certain regions; local manufacturing depends on licensing agreements.
5. How is the supply chain evolving?
Manufacturers are investing in capacity expansion to meet rising demand driven by increasing utilization in KRAS G12C mutations.
References
- Mirati Therapeutics. (2023). Adagrasib (MRTX849) clinical pipeline. https://mirati.com
- WuXi AppTec. (2023). Contract manufacturing services. https://wuXiAppTec.com
- Cambrex. (2023). API and advanced intermediates. https://cambrex.com
- Pharmaceutical Commerce. (2023). Oncology drug manufacturing trends. https://pharmaceuticalcommerce.com
